Moody Aldrich Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Moody Aldrich Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,829	Closed	-$2M	–	202
2026 Q1	$2M	Sell	3,829 -47	-1%	-$22.5K	0.36%	109
2025 Q4	$2.26M	Buy	+3,876	New	+$1.98M	0.42%	105
2024 Q3	–	Sell	-4,814	Closed	-$1.35M	–	207
2024 Q2	$1.35M	Sell	4,814 -310	-6%	-$73.8K	0.26%	108
2024 Q1	$1.37M	Sell	5,124 -4,099	-44%	-$966K	0.23%	115
2023 Q4	$2.13M	Sell	9,223 -4,356	-32%	-$762K	0.38%	94
2023 Q3	$1.98M	Buy	13,579 +2,653	+24%	+$499K	0.38%	89
2023 Q2	$2.52M	Buy	10,926 +3,746	+52%	+$1.01M	0.49%	82
2023 Q1	$1.74M	Buy	+7,180	New	+$1.96M	0.35%	95
2018 Q4	–	Sell	-10,467	Closed	-$2.24M	–	104
2018 Q3	$2.24M	Buy	10,467 +5,395	+106%	+$1.35M	0.65%	75
2018 Q2	$1.42M	Buy	+5,072	New	+$891K	0.5%	80

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Moody Aldrich Partners's MDGL Position: Q2 2026 in Review

Moody Aldrich Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 3,829 shares — an estimated $2M sold.

Moody Aldrich Partners first reported a position in MDGL in Q2 2018 and held it in 10 quarters. The position peaked at $2.52M in Q2 2023. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Moody Aldrich Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Moody Aldrich Partners sold 3,829 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2M.
Moody Aldrich Partners first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Moody Aldrich Partners's Madrigal Pharmaceuticals position peaked at $2.52M in Q2 2023.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.